PMID- 36460429
OWN - NLM
STAT- MEDLINE
DCOM- 20221212
LR  - 20221212
IS  - 2013-2514 (Electronic)
IS  - 2013-2514 (Linking)
VI  - 42
IP  - 4
DP  - 2022 Jul-Aug
TI  - Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of 
      chronic kidney disease.
PG  - 390-403
LID - S2013-2514(22)00086-4 [pii]
LID - 10.1016/j.nefroe.2022.08.001 [doi]
AB  - In the last five years, the medical community was astonishingly surprised by the 
      sequential large outcome trials that displayed the renal effects of sodium 
      glucose co-transporter inhibitors (SGLT2Is) in type 2 diabetes mellitus (T2DM) 
      patients with or without chronic kidney disease (CKD). This favorable effect was 
      later disclosed in non-diabetic CKD patients. The EMPA-REG OUTCOME trial was the 
      first trial that showed a reduction for the need for dialysis in patients 
      suffering diabetic kidney disease (DKD) by 55%. This figure is double the score 
      achieved by the angiotensin receptor blocker, Losartan, in RENAAL trial. The need 
      for dialysis in DAPA-CKD trial was reduced in diabetic and non-diabetic CKD 
      patients by 33%. The renal-specific composite outcome was reduced by 39% in 
      EMPA-REG trial, 40% in CANVAS study, 47% in DECLARE-TIMI 58 study, 34% in 
      CREDENCE trial, and 44% in DAPA-CKD trial. The greater surprise is the 
      significant favorable effect of SGLT2Is on overall mortality in CKD patients with 
      or without T2DM. Similar survival benefit was not previously encountered with any 
      of the medications used in CKD patients with or without diabetes. In this review, 
      we disclose the results of the DAPA-CKD trial, the CREDENCE trial and those of 
      several cardiovascular outcome trials (CVOT) that used different SGLT2Is and 
      showed that patients with lower eGFR levels may have greater benefit with respect 
      to cardiovascular morbidity than patients with normal kidney function. In 
      addition, we discuss the different mechanisms of action that explain the renal 
      beneficial effects of SGLT2Is.
CI  - Copyright (c) 2021 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, 
      S.L.U. All rights reserved.
FAU - Sharaf El Din, Usama Abdel Azim
AU  - Sharaf El Din UAA
AD  - Department of Nephrology, School of Medicine, Cairo University, Manial, Cairo 
      11759, Egypt. Electronic address: usamaaas@gmail.com.
FAU - Salem, Mona Mansour
AU  - Salem MM
AD  - Department of Endocrinology, School of Medicine, Cairo University, Manial, Cairo 
      11759, Egypt.
FAU - Abdulazim, Dina Ossama
AU  - Abdulazim DO
AD  - Department of Rheumatology and Rehabilitation, School of Medicine, Cairo 
      University, Manial, Cairo 11759, Egypt.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Nefrologia (Engl Ed)
JT  - Nefrologia
JID - 101778581
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Diabetic Nephropathies/drug therapy
MH  - Glucose
MH  - Renal Dialysis
MH  - *Renal Insufficiency, Chronic/complications/drug therapy
MH  - Sodium
MH  - Clinical Trials as Topic
OTO - NOTNLM
OT  - CKD
OT  - DKD
OT  - Diabetic nephropathy
OT  - Enfermedad renal cronica
OT  - Enfermedad renal diabetica
OT  - Inhibidores de SGLT2
OT  - Nefropatia diabetica
OT  - SGLT2 inhibitors
EDAT- 2022/12/03 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/12/02 21:07
PHST- 2020/10/19 00:00 [received]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2022/12/02 21:07 [entrez]
PHST- 2022/12/03 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
AID - S2013-2514(22)00086-4 [pii]
AID - 10.1016/j.nefroe.2022.08.001 [doi]
PST - ppublish
SO  - Nefrologia (Engl Ed). 2022 Jul-Aug;42(4):390-403. doi: 
      10.1016/j.nefroe.2022.08.001.